Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel urinary biomarker predicts 1-year mortality after discharge from intensive care.
Nkuipou-Kenfack E, Latosinska A, Yang WY, Fournier MC, Blet A, Mujaj B, Thijs L, Feliot E, Gayat E, Mischak H, Staessen JA, Mebazaa A, Zhang ZY; French and European Outcome Registry in Intensive Care Unit Investigators. Nkuipou-Kenfack E, et al. Among authors: blet a. Crit Care. 2020 Jan 9;24(1):10. doi: 10.1186/s13054-019-2686-0. Crit Care. 2020. PMID: 31918764 Free PMC article.
Low cardiac index and stroke volume on admission are associated with poor outcome in critically ill burn patients: a retrospective cohort study.
Soussi S, Deniau B, Ferry A, Levé C, Benyamina M, Maurel V, Chaussard M, Le Cam B, Blet A, Mimoun M, Lambert J, Chaouat M, Mebazaa A, Legrand M; PRONOBURN group. Soussi S, et al. Among authors: blet a. Ann Intensive Care. 2016 Dec;6(1):87. doi: 10.1186/s13613-016-0192-y. Epub 2016 Sep 13. Ann Intensive Care. 2016. PMID: 27620877 Free PMC article.
Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.
Geven C, van Lier D, Blet A, Peelen R, Ten Elzen B, Mebazaa A, Kox M, Pickkers P. Geven C, et al. Among authors: blet a. Br J Clin Pharmacol. 2018 Sep;84(9):2129-2141. doi: 10.1111/bcp.13655. Epub 2018 Jul 3. Br J Clin Pharmacol. 2018. PMID: 29856470 Free PMC article. Clinical Trial.
Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.
Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, Gayat E, Hartmann O, Scigalla P, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, François B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF; AdrenOSS-1 study investigators. Mebazaa A, et al. Among authors: blet a. Crit Care. 2018 Dec 21;22(1):354. doi: 10.1186/s13054-018-2243-2. Crit Care. 2018. PMID: 30583748 Free PMC article.
A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
Geven C, Blet A, Kox M, Hartmann O, Scigalla P, Zimmermann J, Marx G, Laterre PF, Mebazaa A, Pickkers P. Geven C, et al. Among authors: blet a. BMJ Open. 2019 Feb 19;9(2):e024475. doi: 10.1136/bmjopen-2018-024475. BMJ Open. 2019. PMID: 30782906 Free PMC article.
63 results